Healthcare Common Procedure Coding System Quarterly Update

Effective October 1, 2022

The Centers for Medicare and Medicaid Services (CMS) publishes updates to the Healthcare Procedure Coding System (HCPCS) on a quarterly basis. Public use files may be downloaded from the “HCPCS Quarterly Update” page. Be sure to update any systems accordingly.

Proprietary Lab Analyses (PLA)

No PLA codes were part of the October 2022 update.

Drugs

NEW Codes

C9142 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
C9101 Injection, oliceridine, 0.1 mg
J1932 Injection, lanreotide, (cipla), 1 mg
J9274 Injection, tebentafusp-tebn, 1 mcg
J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cell, including leukopheresis and dose preparation procedures, per therapeutic use
Q5125 injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg

Pass-Through status change

J1952 Leuprolide injectable, camcevi, 1 mg: Pass through status from E2 to G

Discontinued codes

C9095 Injection, tebentafusp-tebn, 1 mcg
C9096 Injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg
C9098 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukopheresis and dose preparation procedures, per therapeutic dose